Carcinogenicity of medicinal drugs: A survey of IARC monographs

Central European Journal of Public Health

Volumn 8, Issue SUPPL., 2000, Pages 83-85

  Torok G ^a   Csik M ^a   Pinter A ^a   Surjan A ^a  

^a Jozsef Fodor National Center for Public Health   (Hungary)

Author keywords

Carcinogenicity; Drugs; IARC

Indexed keywords

ALKYLATING AGENT; ANABOLIC AGENT; ANALGESIC AGENT; ANDROGEN; ANTINEOPLASTIC AGENT; ARSENIC DERIVATIVE; AZACITIDINE; AZATHIOPRINE; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORNAPHAZINE; CHLOROZOTOCIN; CISPLATIN; COAL TAR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIETHYLSTILBESTROL; DOXORUBICIN; ESTROGEN; LOMUSTINE; MELPHALAN; METHOXSALEN; ORAL CONTRACEPTIVE AGENT; PHENACETIN; SEMUSTINE; TAMOXIFEN; THIOTEPA; TREOSULFAN; UNINDEXED DRUG;

ANIMAL CELL; CHROMOSOME ABERRATION; CONFERENCE PAPER; DRUG CARCINOGENICITY; DRUG LEGISLATION; ESTROGEN THERAPY; GENOTOXICITY; HUMAN; LYMPHOMA CELL; MOUSE; MUTAGEN TESTING; NONHUMAN; SALMONELLA TYPHIMURIUM; SKIN DISEASE; TARGET ORGAN; ULTRAVIOLET A RADIATION;

ANIMALS; CARCINOGENICITY TESTS; CHROMOSOME ABERRATIONS; MICE; MUTAGENICITY TESTS; PHARMACEUTICAL PREPARATIONS; SALMONELLA TYPHIMURIUM; SISTER CHROMATID EXCHANGE; TUMOR CELLS, CULTURED;

EID: 0033914277     PISSN: 12107778     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol 1-69. Lyon, International Agency for Research on Cancer, 1972-1997.
2. McGregor, D. B.: Chemicals classified by IARC. their potency in tests for carcinogenicity in rodents and their genotoxicity and acute toxicity In: Vainio, H et al. ed Mechanisms of Carcinogenesis in Risk Identification IARC Sci. Publ. No. 116 pp. 323-352. IARC, 1992
3. Waters, M. N., Stack, H. F., Jackson, M. A.: Short-term tests for defining mutagenic carcinogens. In: McGregor, D. B. et al. ed. The use of short- and medium-term tests for carcinogens and data on genetic effects in carcinogenic hazard evaluation. IARC Sci. Publ. No. 146. pp. 499-536. IARC, 1992
4. Puri, E. C., Baumeister, M., Fautz, R. et al.: Inter-laboratory ring trial of in vitro DNA repair test using rat hepatocytes: further testing and conclusing remarks Mutagenesis 6, 1991, 471-478.
5. Tinwell, H., Ashby, J.: Activity of the human carcinogen MeCCNU in the mouse bone marrow micronucleus assay. Environ. Mol. Mutagen 17, 1991, 152-154.
6. Davies, R., Oreffo, V. I., Martin, E. A. et al.: Tamoxifen causes gene mutations in the livers of lambda/lacl transgenic rats. Cancer Res. 57, 1997, 1288-1893.
7. Glatt, H., Davis, W., Hermersdorfer, H. et al.: Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 19, 1998, 1709-1713
8. Zhu, S., Zeiger, E-: Mutagenicity of the human carcinogen treosulphan, and its hydrolysis producl, dl-1,2:3,4-diepoxybutane in mammalian cells Environ. Mol. Mutagen. 21, 1993, 95-99
9. Zeiger, E., Pagano, D. A.: Mutagenicity of the human carcinogen treosulphan in Salmonella Environ Mol. Mutagen 13, 1989, 343-346
10. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Supplement 7, International Agency for Research on Cancer, Lyon, 1987
11. Santella, R. M., Nunes, M. G., Blaskovic, R. et al.: Quantitation of polycyclic hydrocarbons, 1-hydroxypyrene, and mutagenicity in urine of coal tar-treated psoriasis patients and untreated volunteers. Cancer Epidemiol. Biomarkers Prev 3, 1994, 137-140
12. Kransmuller, S., Parzefall, W., Helma, C. et al.: Toxic effects at griseofulvin: disease models, mechanisms, and risk assessment, Crit. Rev Toxicol. 27, 1997, 495-537.
13. Ferguson, L. R., Hill, C. L., Morecombe, P.: Induction of resistance to 6-thioguanine and cytarabine by a range of anticancer drugs in Chinese hamsier AA8 cells. Eur J. Cancer 4-5, 1992, 736-742
14. Westendorf, J., Marquardt, H., Marquardt, H.: Structure-activity relationship of anthracycline-induced genotoxicity in vitro. Cancer Res. 44, 1984, 5599-5604.